We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Wall Street's Insights Into Key Metrics Ahead of Amneal (AMRX) Q2 Earnings
Read MoreHide Full Article
Wall Street analysts forecast that Amneal Pharmaceuticals (AMRX - Free Report) will report quarterly earnings of $0.14 per share in its upcoming release, pointing to a year-over-year decline of 26.3%. It is anticipated that revenues will amount to $657.43 million, exhibiting an increase of 9.8% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 4.4% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Amneal metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts predict that the 'Net Revenue- Generics Segment' will reach $392.77 million. The estimate points to a change of +5.1% from the year-ago quarter.
The consensus among analysts is that 'Net Revenue- AvKARE Segment' will reach $157.51 million. The estimate indicates a change of +22.7% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Net Revenue- Specialty Segment' of $107.15 million. The estimate indicates a year-over-year change of +10.5%.
Shares of Amneal have demonstrated returns of +1% over the past month compared to the Zacks S&P 500 composite's -5.9% change. With a Zacks Rank #2 (Buy), AMRX is expected to beat the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Wall Street's Insights Into Key Metrics Ahead of Amneal (AMRX) Q2 Earnings
Wall Street analysts forecast that Amneal Pharmaceuticals (AMRX - Free Report) will report quarterly earnings of $0.14 per share in its upcoming release, pointing to a year-over-year decline of 26.3%. It is anticipated that revenues will amount to $657.43 million, exhibiting an increase of 9.8% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 4.4% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Amneal metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts predict that the 'Net Revenue- Generics Segment' will reach $392.77 million. The estimate points to a change of +5.1% from the year-ago quarter.
The consensus among analysts is that 'Net Revenue- AvKARE Segment' will reach $157.51 million. The estimate indicates a change of +22.7% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Net Revenue- Specialty Segment' of $107.15 million. The estimate indicates a year-over-year change of +10.5%.
View all Key Company Metrics for Amneal here>>>
Shares of Amneal have demonstrated returns of +1% over the past month compared to the Zacks S&P 500 composite's -5.9% change. With a Zacks Rank #2 (Buy), AMRX is expected to beat the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>